Immunology in medical practice. VIII. The role of cytokines in the pathogenesis of bacterial infections;Immunologie in de medische praktijk. VIII. De rol van cytokinen in de pathogenese van bacteriele infectieziekten

Nederlands Tijdschrift voor Geneeskunde

Volumn 142, Issue 1, 1998, Pages 14-17

  Van Der Poll, T ^a   Speelman, P ^a   Van Deventer, S J H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ARTICLE; BACTERIAL INFECTION; CELL COMPARTMENTALIZATION; CELL TYPE; IMMUNOLOGY; INFLAMMATION; MEDICAL PRACTICE; PATHOGENESIS; SEPSIS;

BACTERIAL INFECTIONS; CYTOKINES; HUMANS; INTERLEUKIN-1; INTERLEUKIN-10; MULTIPLE ORGAN FAILURE; RECEPTORS, INTERLEUKIN-1; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032477591     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Poll T van der, Lowry SF. Endogenous mechanisms regulating TNF and IL-I during sepsis. In: Vincent JL. editor. Yearbook of Intensive Care and Emergency Medicine 1995. New York: Springer, 1995;385-97.
2. Poll T van der, Lowry SF. Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense? Shock 1995;3:1-12.
3. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
4. Lowry SF, Calvano SE, Poll T van der. Measurement of inflammatory mediators in clinical sepsis. In: Sibbald WJ, Vincent JL, editors. Clinical Trials for the Treatment of Sepsis New York: Springer, 1995:86-105.
5. Dehoux MS, Boutten A, Ostinelli J, Seta N, Dombret MC, Crestani B, et al. Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1994; 150:710-6.
6. Jansen PM, Pouw Kraan TCTM van der, Jong IW de, Mierlo G van, Wijdencs J, Chang AA, et al. Release of interleukin-12 in experimental Escherichia coli septic shock in baboons: relations to plasma levels of interleukin-10 and interferon-gamma. Blood 1996;87:5144-51.
7. Pajkrt D, Poll T van der, Deventer SJH van. Inflammatory responses during human endotoxemia. In: Vincent JL, editor. Yearbook of Intensive Care and Emergency Medicine 1997. New York: Springer, 1997:14-30.
8. Echtenacher B, Falk W, Mannel DN, Krammer PH, Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990;145:3762-6.
9. Poll T van der, Keogh CV, Buurman WA, Lowry SF. Passive immunization against tumor necrosis factor-alpha impairs host defense during pneumococcal pneumonia in mice. Am J Respir Crit Care Med 1997;155:603-8.
10. Poll T van der, Deventer SJH van. The role of interleukin 6 in endotoxin-induced inflammatory responses. Prog Clin Biol Res [ter perse]
11. Gerard C, Bruyns C, Marchant A, Abramowicz D, Vandenabeele P, Delvaux A, et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993;177:547-50.
12. Berg DJ, Kuhn R, Rajewsky K, Muller W, Menon S, Davidson N, et al. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest 1995;96:2339-47.
13. Poll T van der, Marchant A, Keogh CV, Goldman M, Lowry SF. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 1996;174:994-1000.
14. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995;273:934-41.
15. Fisher jr CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of septic shock with the tumor necrosis factor receptor Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996;334:1697-702.
16. Fisher jr CJ, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-Ira Sepsis Syndrome Study Group. JAMA 1994;271 1836-43.